Stephanie D. Burr

Stephanie D. Burr

Auto-generated profile, based on publicly available information

Stephanie D. Burr

Department of Biochemistry and Molecular Biology; Mayo Clinic College of Medicine & Science, Rochester, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SJScott M. Johnson
Scott M. Johnson
HBHanmei Bao
Hanmei Bao
CMCailin E. McMahon
Cailin E. McMahon
YCYongbin Chen
Yongbin Chen
SBStephanie D. Burr
Stephanie D. Burr
JLJun Liu
Jun Liu
The I148M variant of PNPLA3 is closely associated with hepatic steatosis. Recent evidence indicates that the I148M mutant functions as an inhibitor of PNPLA2/ATGL-mediated lipolysis, leaving the role of wild-type PNPLA3 undefined. Despite showing a triglyceride hydrolase activity in vitro, PNPLA3 has yet to be established as a lipase in vivo. Here, we show that PNPLA3 preferentially hydrolyzes polyunsaturated triglycerides, mobilizing polyunsaturated fatty acids for phospholipid desaturation and enhancing hepatic secretion of triglyceride-rich lipoproteins. Under lipogenic conditions, mice with liver-specific knockout or acute knockdown of PNPLA3 exhibit aggravated liver steatosis and reduced plasma VLDL-triglyceride levels. Similarly, I148M-knockin mice show decreased hepatic triglyceride secretion during lipogenic stimulation. Our results highlight a specific context whereby the wild-type PNPLA3 facilitates the balance between hepatic triglyceride storage and secretion, and suggest the potential contribution of a loss-of-function by the I148M variant to the development of fatty liver disease in humans.